Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo BID	21
Overall Study	STARTED	Omecamtiv Mecarbil 25 mg BID	21
Overall Study	STARTED	Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose	19
Overall Study	STARTED	Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose	20
Overall Study	COMPLETED	Placebo BID	21
Overall Study	COMPLETED	Omecamtiv Mecarbil 25 mg BID	20
Overall Study	COMPLETED	Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose	19
Overall Study	COMPLETED	Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose	20
Overall Study	NOT COMPLETED	Placebo BID	0
Overall Study	NOT COMPLETED	Omecamtiv Mecarbil 25 mg BID	1
Overall Study	NOT COMPLETED	Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose	0
Overall Study	NOT COMPLETED	Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose	0

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02695420/flow